Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02327078 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 307
- Enrollment target
NCT02327078 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 307 participants.
The verdict
NCT02327078, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 307 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Epacadostat
- DRUG Nivolumab
- DRUG Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2014-11-26 |
| Est. Completion | 2020-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02327078
The ClinicalTrials.gov registry entry for NCT02327078 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epacadostat is the first listed.
NCT02327078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02327078 about?
NCT02327078 is a clinical study titled "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)". This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacad...
What is the current status of trial NCT02327078?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 307 participants. The study started on 2014-11-26. Estimated completion is 2020-06-16.
What interventions are being tested in trial NCT02327078?
The interventions under investigation include: Epacadostat (DRUG), Nivolumab (DRUG), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02327078?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.